Our founders Kevin Maskell and Lili Wang have just returned from presenting at this year’s Biotech Showcase during JPM2025. Kevin presented on Bioarchitech’s cutting-edge cancer immunotherapy platform and showcased the potential of our lead candidate, BA-V151.

The feedback was overwhelmingly positive from those we met, with industry leaders and potential partners recognizing BA-V151’s innovative approach to enhancing the efficacy of existing cancer antibody therapies. 

Thank you to everyone who connected with us at the event—we’re energized by your enthusiasm and look forward to following up with new partners as we advance BA-V151 toward its next milestones.